ICAM1 (Intercellular adhesion molecule 1)

News alerts, weekly reports and conference planners

Entrez ID:

ICAM1 elevation	Gastric Cancer	ICAM1 elevation	Gastric Cancer	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3
ICAM1 overexpression	Breast Cancer	ICAM1 overexpression	Breast Cancer	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D
ICAM1 overexpression	Multiple Myeloma	ICAM1 overexpression	Multiple Myeloma	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D
ICAM1 overexpression	Gastric Cancer	ICAM1 overexpression	Gastric Cancer	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D
ICAM1 elevation	Solid Tumor	ICAM1 elevation	Solid Tumor	PD1 inhibitor + PD-L1 inhibitor Resistant: D – Preclinical PD1 inhibitor + PD-L1 inhibitor Resistant : D	PD1 inhibitor + PD-L1 inhibitor Resistant: D – Preclinical PD1 inhibitor + PD-L1 inhibitor Resistant : D

Associations(5)